PM 534
Alternative Names: PM-534Latest Information Update: 13 Jun 2023
At a glance
- Originator PharmaMar
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 07 Jun 2023 Pharmacodynamics data from preclinical study in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 23 Dec 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Spain (IV) (NCT05835609)